Redefining fatty liver as metabolic dysfunction-associated steatotic liver disease: Implications of nomenclature changes for patients with diabetes

Figure 1 The diagnostic frameworks for non-alcoholic fatty liver disease, metabolic dysfunction-associated fatty liver disease, metabolic dysfunction-associated steatotic liver disease, and metabolic and alcohol-associated liver disease differ significantly. ALD: Alcohol-associated liver disease; HBV: Hepatitis B virus; HCV: Hepatitis C virus; NAFLD: Non-alcoholic fatty liver disease; MAFLD: Metabolic dysfunction-associated fatty liver disease; MetALD: Metabolic and alcohol-associated liver disease; MASLD: Metabolic dysfunction-associated steatotic liver disease; T2DM: Type 2 diabetes mellitus; HDL: High-density lipoprotein; BMI: Body mass index; WC: Waist circumference; HOMA-IR: Homeostatic model assessment for insulin resistance.

Figure 2 Challenges and future directions. AI: Artificial intelligence; EHRs: Electronic health records; T2DM: Type 2 diabetes mellitus; MASLD: Metabolic dysfunction-associated steatotic liver disease; NAFLD: Non-alcoholic fatty liver disease.